Breaking News Instant updates and real-time market news.

PFE

Pfizer

$36.38

-0.48 (-1.30%)

11:48
01/08/18
01/08
11:48
01/08/18
11:48

Pfizer sees up to 15 potential blockbuster approvals in five years

Comments are from the JP Morgan Healthcare Conference.

  • 08

    Jan

  • 08

    Jan

  • 25

    Jan

  • 30

    Jan

  • 06

    Feb

  • 08

    Feb

  • 16

    Feb

PFE Pfizer
$36.38

-0.48 (-1.30%)

11/13/17
PIPR
11/13/17
NO CHANGE
Target $54
PIPR
Overweight
Pfizer still most compelling risk/reward in global pharma, says Piper Jaffray
Piper Jaffray analyst Richard Purkis says Pfizer remains the most compelling long-run risk/reward opportunity in his global pharma coverage universe. He believes the company's key growth assets, or Ibrance, Eliquis, Xtandi, Xeljanz and Bosulif, and pipeline are being underestimated by investors. Pfizer remains one of the analyst's top 2017 picks. Purkis reiterates an Overweight rating on the shares with a $54 price target.
11/13/17
BMOC
11/13/17
NO CHANGE
BMOC
BMO says Pfizer buying Biogen makes more sense than deal for Bristol-Myers
BMO Capital analyst Alex Arfaei noted the "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that Pfizer could target Bristol-Myers (BMY), Arfaei argues that a deal for Biogen (BIIB) would make more sense. He believes Pfizer has a significant gap in neurology, particularly in Alzheimer's, where it cannot afford to remain on the sidelines as its peers - including Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) - all have pivotal trials in that area reading out in 2019-2020. Pfizer could have an opportunity to leverage near-term volatility in Biogen's MS franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development, he tells investors.
11/14/17
WELS
11/14/17
NO CHANGE
Target $12
WELS
Outperform
Pfizer ADHD drug supply shortage is positive for Neos, says Wells Fargo
Wells Fargo analyst David Maris says Pfizer (PFE) has sent a letter on physicians dated November 8th telling them of a supply shortage for its liquid and chewable methylphenidate ADHD products. Maris says Pfizer's product is a direct competitor of Neos' (NEOS) recently-launched Cotempla XR-ODT, adding Neos will benefit from having its primary competition in the alternative dose market facing a shortage. The analyst says Cotempla XR-ODT, launched in September, is off to a very strong start, keeping his Outperform rating with a $12 price target on Neos.
12/05/17
SBSH
12/05/17
NO CHANGE
Target $72
SBSH
Buy
Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi
The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.

TODAY'S FREE FLY STORIES

K

Kellogg

$62.31

0.79 (1.28%)

08:06
05/24/18
05/24
08:06
05/24/18
08:06
Recommendations
Kellogg analyst commentary  »

Kellogg offers attractive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 25

    May

AXDX

Accelerate Diagnostics

$21.05

-0.35 (-1.64%)

08:05
05/24/18
05/24
08:05
05/24/18
08:05
Initiation
Accelerate Diagnostics initiated  »

Accelerate Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

V

Visa

$131.90

1.185 (0.91%)

08:05
05/24/18
05/24
08:05
05/24/18
08:05
Hot Stocks
Visa announces strategic investment in YellowPepper »

Visa announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTM

Tata Motors

$22.39

-0.52 (-2.27%)

08:04
05/24/18
05/24
08:04
05/24/18
08:04
Technical Analysis
Technical Take: Tata Motors down for second session to new 52-week low »

In pre-market trading the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEF

Jefferies Financial Group

$23.47

-0.045 (-0.19%)

08:03
05/24/18
05/24
08:03
05/24/18
08:03
Hot Stocks
BattleFin names Jefferies as exclusive investment banking partner »

BattleFin announces an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:03
05/24/18
05/24
08:03
05/24/18
08:03
Conference/Events
Deutsche Bank to hold a conference »

Future Metals Corporate…

CEMI

Chembio Diagnostics

$8.70

-0.1 (-1.14%)

08:03
05/24/18
05/24
08:03
05/24/18
08:03
Hot Stocks
Chembio Diagnostics to commercialize disease tests in Brazil »

Chembio Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

FHB

First Hawaiian

$28.94

0.07 (0.24%)

08:03
05/24/18
05/24
08:03
05/24/18
08:03
Conference/Events
First Hawaiian management to meet with Deutsche Bank »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

08:02
05/24/18
05/24
08:02
05/24/18
08:02
Conference/Events
Jefferies to hold a conference »

Automotive Aftermarket…

08:02
05/24/18
05/24
08:02
05/24/18
08:02
Conference/Events
Morgan Stanley to hold a symposium »

2nd Annual Small &…

MYO

Myomo

$3.28

-0.02 (-0.61%)

08:02
05/24/18
05/24
08:02
05/24/18
08:02
Hot Stocks
Myomo announces MyoPro availability in 16 new U.S. locations »

Myomo announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKY

Skyline

$29.22

-0.56 (-1.88%)

08:01
05/24/18
05/24
08:01
05/24/18
08:01
Initiation
Skyline initiated  »

Skyline initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BX

Blackstone

$31.79

-0.08 (-0.25%)

08:01
05/24/18
05/24
08:01
05/24/18
08:01
Conference/Events
Detroit Economic Club to hold a luncheon »

Tony James, Executive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 30

    May

WHR

Whirlpool

$164.63

0.3 (0.18%)

08:01
05/24/18
05/24
08:01
05/24/18
08:01
Hot Stocks
Whirlpool announces preliminary results of modified Dutch auction tender offer »

Whirlpool Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

HFC

HollyFrontier

$73.67

0.75 (1.03%)

08:00
05/24/18
05/24
08:00
05/24/18
08:00
Recommendations
HollyFrontier analyst commentary  »

HollyFrontier price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$36.72

0.35 (0.96%)

08:00
05/24/18
05/24
08:00
05/24/18
08:00
Options
JD.com call buyer realizes 1% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNP

Union Pacific

$144.26

1.36 (0.95%)

07:59
05/24/18
05/24
07:59
05/24/18
07:59
Initiation
Union Pacific initiated  »

Union Pacific resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

NCR

NCR Corp.

$30.75

-0.4 (-1.28%)

07:58
05/24/18
05/24
07:58
05/24/18
07:58
Recommendations
NCR Corp. analyst commentary  »

NCR Corp. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:55
05/24/18
05/24
07:55
05/24/18
07:55
Conference/Events
Federal Reserve Bank of Philadelphia President speaks at a conference »

Philadelphia Federal…

MCRB

Seres Therapeutics

$8.12

0.16 (2.01%)

07:55
05/24/18
05/24
07:55
05/24/18
07:55
Conference/Events
Seres Therapeutics to hold a research and development day »

Microbiome Research &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 02

    Jun

OKTA

Okta

$49.49

0.99 (2.04%)

07:52
05/24/18
05/24
07:52
05/24/18
07:52
Recommendations
Okta analyst commentary  »

Okta price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 06

    Jun

  • 12

    Jun

INTU

Intuit

$196.15

5.74 (3.01%)

07:51
05/24/18
05/24
07:51
05/24/18
07:51
Recommendations
Intuit analyst commentary  »

Intuit price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

CIT

CIT Group

$55.27

-0.06 (-0.11%)

07:51
05/24/18
05/24
07:51
05/24/18
07:51
Hot Stocks
CIT Group announces preliminary results of cash tender offer for common stock »

CIT Group announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EDU

New Oriental Education

$101.38

4.82 (4.99%)

07:50
05/24/18
05/24
07:50
05/24/18
07:50
Downgrade
New Oriental Education rating change  »

New Oriental Education…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

TAL

TAL Education

$43.74

1.11 (2.60%)

07:50
05/24/18
05/24
07:50
05/24/18
07:50
Upgrade
TAL Education rating change  »

TAL Education upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.